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Abstract 
Red blood cells (RBC) coated with antibody (immunoerythrocytes) may be useful for drug targeting. Previously we have developed a 
methodology for avidin (streptavidin)-mediated attachment of biotinylated antibodies (b-Ab) to biotinylated RBC (B-RBC). We have 
observed that binding of avidin to B-RBC in suspension leads to their complement-mediated lysis by autologous erum. In the present 
work we have studied the interaction of B-RBC, which are not complement susceptible, with immobilized avidin and their consequent 
susceptibility to lysis by complement. B-RBC adhered tightly to avidin-coated surfaces and were rendered susceptible to lysis by 
autologous erum. A long biotin ester provided more effective binding of the B-RBC to immobilized avidin and greater lysis by 
complement, than a short biotin ester. Based on these results, we have hypothesized that targeting of serum-stable drug-loaded B-RBC 
attained by step-wise administration of b-Ab and streptavidin may provide target-sensitive lysis of B-RBC. To confirm this hypothesis, 
we have studied b-Ab and streptavidin mediated targeting of B-RBC to immobilized antigen. Step-wise addition of biotinylated antibody, 
avidin or streptavidin and b-RBC caused specific binding of B-RBC to immobilized antigen and their subsequent lysis by autologous 
serum. Therefore, our results obtained in an in vitro model demonstrate hat B-RBC might be used for targeting and local release of drug. 
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1. Introduction 
The aim of targeting is to achieve an accumulation of a 
drug at a specific site after systemic administration [1,2]. 
Several methods for drug targeting have been proposed, 
including packaging in liposomes and red blood cells 
(RBC) bearing antibody to target antigens [1-3]. Targeting 
of immunoliposomes loaded with various drugs has been 
studied in various animal models, including targeting to 
tumors [4-6], endothelial cells [7] and macrophages [8,9]. 
Recent studies demonstrate hat modification of liposomes 
with polyethylene glycol [5,10,11] and gangliosides [12], 
as well as utilization of specific lipid composition [13] 
provide prolongation of the lifespan of liposomes in the 
bloodstream. Meanwhile, immunogenicity and the uptake 
Abbreviations: RBC, red blood cell; B-RBC, biotinylated red blood 
cell; Av, avidin. 
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of liposomes by reticuloendothelial tissue are of concern in 
terms of the safety of liposomes utilization [14]. 
RBC represent a second potential carrier for drug deliv- 
ery. The most important difference between liposomes and 
RBC is their size: RBC are particles of 5-10 /xm in 
various animal species, whereas liposomes vary in the 
range 100-1000 nm. Therefore, liposomes are capable of 
filtration into tissues, and as such are preferable for the 
targeting of drugs to tissues (e.g., for tumor targeting [15]). 
As RBC can not filtrate in the tissues, they can interact 
with intravascular targets only. Association with RBC 
should reduce the filtration of a drug in the tissues and, 
therefore, reduce the side effects of a drug. 
Autologous RBC are a non-immunogenic, physiologic 
and available carrier for drug targeting [3,16]. RBC pos- 
sess a large inner volume and thus offer the advantage of 
prolonged circulation of a large dose of encapsulated drug 
in the organism [17]. RBC may be used for drug delivery 
to various intravascular targets including endothelial cells, 
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macrophages [ 18], blood cells [ 19] and immunocompetent 
cells [20]. Components of the extracellular matrix exposed 
to the bloodstream in sites of vessel injury (collagen, e.g.) 
may also represent a target for immunoerythrocytes [21]. 
For example, immunoerythrocytes could be used for the 
delivery of inhibitor(s) of arachidonic acid metabolism to 
the sites of the vascular injury, in order to prevent he 
aggregation of platelets and reduce inflammation [22]. 
Delivery of anticoagulant agents (hirudin, e.g., [23]) to the 
injured blood vessel(s) could also be considered as an area 
of application of RBC-mediated targeting. 
During the last decade we have investigated a targeting 
strategy using avidin-mediated attachment of biotinylated 
antibody to the surface of biotinylated RBC (B-RBC). 
RBC biotinylation is a relatively simple procedure provid- 
ing sites for high-affinity attachment of avidin or strepta- 
vidin [24-26]. There are two strategies for immunotarget- 
ing of B-RBC loaded with a drug. First, biotinylated 
antibody can be attached to B-RBC via streptavidin (one- 
step targeting). Such immunoerythrocytes possess high 
affinity to the targets [21,25,27]. Second, biotinylated anti- 
body and streptavidin may be injected at the first stage 
followed by injection of drug-loaded B-RBC (two- or 
three-step targeting, developed recently in nuclear medicine 
[28-31]). 
B-RBC are stable in serum and do not undergo intravas- 
cular lysis in either animals [32-34] or humans [35]. 
However, addition of avidin or streptavidin to a suspension 
of B-RBC renders the cells susceptible to lysis by autolo- 
gous complement via the alternative pathway [36]. If inter- 
action of avidin (streptavidin) with B-RBC could be re- 
stricted to the target, then consequent lysis by complement 
could be utilized to cause local release of drug. One 
possible strategy would be to deliver complement-stable, 
drug-loaded B-RBC to a target by sequential administra- 
tion of biotinylated target-specific antibody, avidin 
(streptavidin) and B-RBC. Systemic injection of biotinyl- 
ated antibodies followed by streptavidin has been shown to 
provide targeting of streptavidin in animals [28,29] and 
humans [30,31]. Importantly, excess streptavidin and bio- 
tinylated antibody are rapidly eliminated from the circula- 
tion due to polyvalent interaction of avidin with biotinyl- 
ated antibodies and fast liver uptake of the complexes [37]. 
B-RBC injected into the circulation would then bind to the 
target due to interaction with avidin already bound to the 
target. Subsequently, complement-mediated lysis of the 
target-bound B-RBCs would release the drug, thus provid- 
ing high local concentration of a drug in the target zone. 
A requirement for this strategy is that B-RBC attached 
to avidin already bound to the target antigen are rendered 
susceptible to lysis by complement. However, interaction 
of B-RBC with immobilized avidin has not been previ- 
ously investigated and the resultant susceptibility to com- 
plement lysis may differ from that in suspension due to 
steric considerations. In the present work, we have investi- 
gated this possibility using RBC biotinylated with biotin 
N-hydroxysuccinimide ester ('short biotin ester, SB-RBC') 
and with 6-biotinylamidocaproic a id N-hydroxysucci- 
nimide ester ('long biotin ester, LB-RBC'). We have 
examined in vitro the targeting of B-RBC to immobilized 
avidin and also to immobilized antigen via biotinylated 
antibody and avidin (streptavidin). The results demonstrate 
that B-RBC bound to avidin immobilized either directly or 
via biotinylated antibody are specifically rendered suscep- 
tible to lysis by complement. 
2. Materials and methods 
2.1. Materials 
Avidin was purified from hen egg white as described in 
[38], streptavidin was from Calbiochem (San Diego, CA). 
RBC were obtained from healthy volunteers. Fresh autolo- 
gous serum or pooled human serum of the same blood 
group (prepared from the blood of healthy volunteers) was 
used as a source of complement. Bovine serum albumin 
(BSA), biotin N-hydroxysuccinimide ester (short biotin 
ester, SB), 6-biotinylamidocaproic acid N-hydroxysucci- 
nimide ester (long biotin ester, LB) and human fibrinogen 
were from Sigma (St. Louis, MO). Avidin was labeled 
with [~zsI]-Bolton-Hunter r agent from Amersham (UK), 
according to the manufacturers instructions. Isotonic 
veronal-buffered saline (3 mM diethylbarbituric acid, 1 
mM sodium salt of diethylbarbituric a id, 145 mM NaC1, 
1.8 mM MgC12, 0.5 mM CaC12, pH 7.4; VBS) containing 
1 mg/ml BSA (VBS-BSA) was used as diluent in all 
studies. 
2.2. BiotinyIation of  RBC 
Biotinylation of RBC was performed as described pre- 
viously [25]. Briefly, sodium tetraborate (0.1 ml 0.1 M, pH 
9.0) and biotin ester (3 /zl of 0.1 M solution in dimethyl 
formamide, DMF) were added to 1 ml of 10% suspension 
of RBC in saline. After 30 min incubation at room temper- 
ature, B-RBC were washed by centrifugation i VBS. To 
estimate number of biotin residues on the B-RBC mem- 
brane we used the method of Suzuki and Dale [32,33]. 
Briefly, we have incubated B-RBC with radiolabeled avidin 
for 1 h at room temperature, liminated non-bound avidin 
via standard washing by centrifugation and determined 
B-RBC-bound radioactivity in a gamma-counter. By this 
assay, the standard procedure of biotinylation provides 
about l0 6 avidin-accessible biotin residues per RBC. 
2.3. Binding of  B-RBC to immobilized avidin 
For avidin immobilization, avidin (5 /xg in 0.25 ml 
VBS) was incubated overnight at 4°C in multiwell culture 
plates ('Nunc', USA). Control wells were incubated with 
VBS-BSA instead of avidin. The plates were washed 5 
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times with distilled water to remove unbound avidin, incu- 
bated for 1 h with VBS-BSA to block non-specific binding 
sites and washed 5 times with distilled water. To determine 
the surface density of immobilized avidin, radiolabeled 
avidin was immobilized in the wells as described. After 
washing out of non-bound avidin, immobilized radiola- 
beled avidin was eluted from wells by boiled SDS solution 
and bound radioactivity was measured in a RackGamma 
counter (LKB, Sweden). 
To study the binding of b-RBC to avidin-coated sur- 
faces, 0.3 ml of VBS-BSA and 25 /xl of 10% B-RBC or 
native RBC suspension were added to the wells and incu- 
bated for 1 h at room temperature. Unbound cells were 
washed away with saline. Then 0.3 ml of distilled water 
was added to each well. 10 min later, hemoglobin ab- 
sorbance at 405 nm was measured in lysates to determine 
the amount of RBC bound to avidin-coated and to albu- 
min-coated control surfaces. Calibration curves of ab- 
sorbance at 405 nm in lysates of known amounts of RBC 
were made in each experiment o calculate the RBC 
binding. 
2.4. Lysis of B-RBC bound to immobilized avidin 
To study lysis by homologous serum of B-RBC bound 
to immobilized avidin, two methods were employed. The 
first was used to compare lysis of B-RBC incubated in 
avidin-coated and albumin-coated wells, i.e., avidin-bound 
B-RBC and unbound B-RBC. In this case, unbound B-RBC 
were not washed off after the binding step and serum at 
the chosen dilution was added directly to VBS-BSA in the 
well. After a 1 h incubation with serum at 37°C, aliquots 
of supernatants were withdrawn from the wells, avoiding 
disturbance of sedimented cells, and hemoglobin ab- 
sorbance at 405 nm was measured. To correct for 
hemoglobin in serum, the absorbance at 405 nm in corre- 
sponding cell-free serum dilutions was subtracted from 
that obtained in test wells. Wells with serum-free VBS-BSA 
were used as zero lysis standards; 100% lysis was attained 
by the addition of distilled water to the same number of 
B-RBC, The degrees of lysis by water of B-RBC bound 
with immobilized avidin and avidin-free B-RBC were the 
same. 
To evaluate lysis of B-RBC bound to the avidin-coated 
surfaces, unbound B-RBC were washed off after incuba- 
tion of B-RBC with the immobilized avidin. VBS-BSA 
containing human serum was added and wells were incu- 
bated under standard conditions (1 h, 37°C). Lysis was 
estimated by hemoglobin absorbance at 405 nm in super- 
natants, as described above. Binding of B-RBC to the 
immobilized avidin was determined by water lysis in 
parallel wells as described above. 
2.5. Binding of B-RBC to immobilized antigen through 
biotinylated antibody 
Human IgG was immobilized in the wells by overnight 
incubation at 4°C (5 /xg in 250 /zl of VBS per well). The 
plates were washed with water, blocked with VBS-BSA 
and washed again with water. Biotinylated sheep anti-hu- 
man IgG (prepared by standard method [39]) was incu- 
bated in the wells (4/zg in 250/xl of VBS-BSA/well, 1 h 
at room temperature), washed and avidin or streptavidin (5 
/zg in 250 /zl of VBS-BSA/well) was added. After a 1 h 
incubation wells were washed 5 times with water, B-RBC 
were added and incubated for 1 h at 37°C. Unbound 
B-RBC were removed by washing. Binding of B-RBC to 
wells and their subsequent lysis by autologous complement 
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Fig. l. Interaction of biotinylated human red blood cells with avidin. RBC modified with short biotin ester (SB-RBCs, circles) or with long biotin ester 
(LB-RBCs, triangles) were incubated with immobilized avidin (A) or with avidin in suspension (B). Avidin surface density and RBC binding were 
measured as detailed in Section 2. Typical results from a series of four experiments. 
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was measured as described. In a separate experiment, 
control RBC were incubated in the presence of comple- 
ment in the antigen-coated wells pre-treated with biotinyl- 
ated sheep anti-human IgG and avidin. According to 
hemoglobin absorbance in supernatants, lysis of control 
RBC in these wells did not exceed that in BSA-coated 
wells. 
3. Results 
3.1. Binding of biotinylated RBC m immobilized avidin 
Table 1 shows that SB-RBC and LB-RBC bound specif- 
ically to avidin-coated plates, but not to the BSA-coated 
control plate. Native RBC did not bind to either plate. The 
standard procedure (overnight incubation with 5 /zg  avidin 
per well) provided immobilization of 2 • 1012 molecules of 
av id in /cm 2 as calculated from binding of radiolabeled 
avidin. At this surface density of immobil ized avidin, 
about 2 • 10 6 B-RBC bound per cm 2 for both LB and SB 
forms of biotin. Thus, at maximal binding the surface area 
available for each B-RBC is calculated to be 70 /~m 2. The 
human RBC is a disc of 8 /zm diameter and would be 
predicted to occupy an area of about 50 /xm 2. Therefore, 
under these conditions, bound B-RBC occupy approx. 70% 
of the available surface. 
Reduction of the surface density of immobil ized avidin 
(by reducing the quantity of avidin incubated in the wells) 
caused a decrease in the binding of B-RBC. However, this 
decrease was not the same for SB-RBC and LB-RBC, the 
latter bound better at reduced density of immobil ized 
avidin (Fig. 1A). In contrast, when free avidin was added 
to a suspension of B-RBC it bound to a similar degree to 
both SB-RBC and LB-RBC over the range of avidin 
concentrations examined (Fig. 1B). 
3.2. Lysis by homologous serum of biotinylated red blood 
cells bound to immobilized avidin 
While B-RBC were stable in serum in the absence of 
avidin, homologous erum rapidly lysed B-RBC bound to 
immobil ized avidin (Fig. 2). No lysis was observed in the 
Table 1 
Binding of biotinylated RBC to avidin-coated surface 
Coating RBC SB-RBC LB-RBC 
Avidin < 0.1 2.01 +0.2 1.9-1-0.1 
Albumin < 0.1 < 0.1 < 0.1 
Wells coated with 5 t*g of avidin or albumin as control as described in 
Section 2 were incubated with suspensions containing 1.5.10 7 RBC, 
SB-RBC or LB-RBC for 1 h. After washing to remove non-bound RBCs, 
binding of RBCs was measured by detection of hemoglobin absorbance 
in wells after addition of distil led water for hypotonic lysis of bound 
cells. SB, short biotin ester; LB, long biotin ester. Binding is shown as 
RBC bound per cm 2 X' 10 -6, mean +S.E., n = 3. 
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Fig. 2. Biotinylated RBCs are lysed by normal human serum after binding 
to immobilized avidin. (A) SB-RBC (open symbols) and LB-RBC (closed 
symbols) were incubated for 1 h in avidin-coated wells (triangles) or in 
BSA-coated wells (circles). Normal human serum was then added to the 
wells to attain the indicated final dilutions and incubated for a further 1 h 
at 37°C. Hemolysis was measured by hemoglobin release into super- 
natants as detailed in methods. Results are representative of those ob- 
tained in 3 separate experiments. (B) Time course at 37°C of serum lysis 
of B-RBC bound to immobilized avidin. Symbols are the same as in A. 
Hemolysis was measured by hemoglobin release into supernatants a  
detailed in methods. Results are representative of those obtained in 3 
separate experiments. 
absence of serum. Serum induced negligible lysis of native 
(non-biotinylated) RBC incubated in the avidin-coated 
wells (not shown). Lysis of B-RBC incubated in BSA- 
coated wells was negligible as compared with lysis of the 
same cells in the avidin-coated wells. 
Comparison of LB-RBC and SB-RBC revealed that the 
former were rendered more sensitive to complement lysis 
when bound at the same cell density to identical avidin- 
coated surfaces. While absolute values of lysis varied for 
different sera, maximal ysis of immobil ized avidin-bound 
SB-RBC was never higher than 60%, while almost 100% 
lysis was achieved with immobil ized avidin-bound LB- 
RBC (Fig. 2). Because LB-RBC were more susceptible to 
complement lysis than SB-RBC, subsequent studies uti- 
lized LB-RBC. 
At the standard surface density of avidin used in this 
study (2-2.5) -  1012 molecu les /cm 2) almost complete ly- 
sis of avidin-bound LB-RBC was achieved (85-95% of 
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Fig. 3. Influence of the surface density of immobilized avidin on B-RBC 
binding and serum lysis. LB-RBC binding to avidin coated wells (open 
circles) and subsequent lysis by serum (closed circles) were measured as 
detailed in methods. The data are presented as percentage of maximal 
values of binding (8.10 s LB-RBC/cm 2) and lysis (78% lysis) attained at 
avidin surface density of 2.5.1012 molecules of avidin/cm 2.Representa- 
tive results from series of two separate xperiments. 
lysis at a serum dilution of 1:20). A reduction in surface 
density of immobilized avidin to 0.6 • 1012 molecules/cm 2 
caused a decrease in lysis to 40% of that attained at a 
surface density of 2. 1012 molecules/cm 2. In contrast 
with lysis, binding of LB-RBC to avidin remained un- 
changed over this range (Fig. 3). Further eduction of the 
avidin density caused a marked ecrease in LB-RBC bind- 
ing and almost complete limination of lysis. 
3.3. LB-RBC bound to immobilized antigen through bio- 
tinylated antibody and auidin are rendered susceptible to 
lysis by autologous erum 
To test our strategy for local lysis of targeted LB-RBC, 
we studied binding to immobilized antigen through bio- 
tinylated antibody and avidin and subsequent susceptibility 
to lysis by autologous serum. Table 2 shows that step-wise 
incubation of antigen-coated wells with biotinylated anti- 
body and avidin (or streptavidin) provides pecific binding 
of LB-RBC. There was no binding of LB-RBC to antigen- 
coated wells if avidin or biotinylated antibody were omit- 
ted (not shown). Addition of autologous erum caused 
efficient lysis of target-bound LB-RBC in this model. 
Thus, biotinylated LB-RBC, which are stable in serum, can 
be targeted to an antigen-bearing surface and, after binding 
to the target, will be rendered susceptible to complement- 
mediated lysis by autologous serum. 
4. Discussion 
Avidin-biotin technology has achieved a high profile in 
biomedical sciences in the last 15 years. The high affinity 
polyvalent interaction between avidin (streptavidin) and 
biotin or biotinylated molecules has been exploited in 
many immunochemical techniques [39]. During the last 
five years we and others have attempted to explore this 
technology in vivo. Biotinylated antibodies and strepta- 
vidin are used for gamma-immunoimaging in animal mod- 
els and in patients [28-31]. Streptavidin and avidin are 
used for immunotargeting of liposomes [40], for clearance 
of radiolabeled biotinylated antibodies from the circulation 
[37] and for targeted elivery of antigens to immunocom- 
petent cells [41]. Avidin/biotin technology has been uti- 
lized to attach biotinylated antibodies to RBC for RBC- 
mediated elimination of pathogens from the bloodstream 
[42,43]. Avidin- and streptavidin-mediated conjugation of 
biotinylated DNA, peptides and enzymes is useful for 
targeting of these agents to the various organs and tissues 
including brain [44], lung [45] and tumors [46]. 
We have explored the use of avidin (streptavidin) for 
targeted elivery of biotinylated RBC loaded with drug, 
using biotinylated antibody as the primary targeting agent 
[21,25,27]. While investigating the biocompatibility of 
avidin-coated B-RBC, we have observed that attachment 
of avidin or streptavidin to B-RBC in suspension caused 
Table 2 
Interaction of LB-RBC with avidin or streptavidin bound to immobilized antigen through biotinylated antibody cause their lysis by autologous serum 
Coating BSA Avidin IgG IgG 
Targeting none direct B-anti-IgG + AV B-anti-IgG + SA 
LB-RBC bound < 0.1 34.7 + 0.7 32.4 ± 0.7 33.1 ± 1.2 
Lysis 
Serum dilution 
1:5 9.5 ± 0.1 97.7 + 0.0 81.2 -t- 7.3 80.6 + 7.8 
1:10 ND 100.0 -I- 0.0 90.7 ± 5.3 45.7 ± 4.4 
No serum < 5 < 5 < 5 < 5 
Wells coated with human lgG were incubated with biotinylated sheep antibody to human IgG (B-anti-lgG) for 1 h, washed, incubated for l h with avidin 
(AV) or with streptavidin (SA) and washed again. Binding of LB-RBC is shown as a percent of added LB-RBC (106 LB-RBC were added per well), 
mean + S.E., n = 3. Non-specific binding of LB-RBC in IgG-coated wells treated with B-&-IgG only or with avidin only was the same as in BSA-coated 
wells. Lysis by serum is shown as percent of lysis of bound LB-RBC at indicated serum dilution. 
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their lysis by autologous complement via the alternative 
pathway [36]. The combination of these properties of 
avidin interaction with B-RBC (affinity targeting and lysis 
by complement), provides a basis for a new stepwise 
targeting strategy to achieve local release of a drug from 
B-RBC. However, an obligatory requirement for this strat- 
egy is that B-RBC bound through immobilized avidin to 
the target cell are rendered susceptible to lysis. 
The interaction of B-RBC with immobilized avidin and 
their consequent lysis differ in several respects from the 
previously described interaction of B-RBC with free avidin 
in suspension [36]. Notably, B-RBC formed using the long 
ester of biotin bound immobilized avidin more efficiently 
than did those formed using the short ester, and were more 
susceptible to serum lysis (Figs. 1 and 2). We suggest that 
these differences occur because the long biotin ester helps 
to overcome steric limitations imposed upon B-RBC bind- 
ing to immobilized avidin. Presumably, binding of B-RBC 
to immobilize avidin (streptavidin) and consequent com- 
plement-induced lysis should depend on the degree of 
RBC biotinylation, i.e., on the surface density of biotin 
residues on RBC. In the present study we have used RBC 
biotinylated with 1 mM BxNHS, which provides coupling 
of about 10 6 streptavidin-accessible iotin residues per 
RBC. We did not address the interaction of B-RBC pos- 
sessing lower surface densities of biotin residues with 
immobilized avidin. Our preliminary results, however, sug- 
gest that a decrease in the surface density of biotin residues 
on the B-RBC membrane leads to a reduction of B-RBC 
targeting to immobilized streptavidin and antigen (Muzy- 
kantov and Murciano, unpublished results). 
We here demonstrate hat B-RBC bind specifically to 
immobilized avidin and are consequently rendered suscep- 
tible to lysis by autologous serum. Both direct immobiliza- 
tion of avidin on the plastic surface and its targeting to 
immobilized antigen through biotinylated antibody gave 
similar results, confirming the validity of our strategy. 
Both avidin and streptavidin i duced lysis, suggesting that 
streptavidin may be used for targeting and local lysis of 
B-RBC (Table 2). This is important because of the greater 
biocompatibility of streptavidin [47]. 
The concept of the target-sensitive hicle for drug 
targeting was developed first for immunoliposomes by 
Huang and co-workers a decade ago. They have demon- 
strated that interaction of immunoliposomes with immobi- 
lized antigen induces alterations in the physical stability of 
the lipid vesicle and thus leads to target-induced lysis of 
liposomes [48]. We have extended this concept owards 
RBC. RBC are a non-immunogenic, biocompatible and 
available vehicle, possessing large inner volume which can 
be loaded with a drug [2]. The difference in the size of 
immunoliposomes (relatively small particles) and immuno- 
erythrocytes (large particles) suggests that the former would 
be appropriate for targeting to antigens in tissues, whereas 
the latter appear to be appropriate for intravascular target- 
ing of a drug. Target-induced lysis of immunoliposomes 
and immunoerythrocytes differ in their mechanisms, ince 
the latter is mediated by a physiologic mediator, comple- 
ment. 
Our previous studies document that avidin attachment 
to RBC via biotinylated membrane proteins causes lysis, 
while avidin attachment via biotinylated lipids, biotinyi- 
ated ricin or tannin does not, implicating a role for specific 
surface proteins in the process [49-51]. Analysis of b-RBC 
by SDS/PAGE, Western-blotting, and staining of nitro- 
cellulose with streptavidin-peroxidase demonstrated that 
biotinylation leads to coupling of biotin to a variety of 
RBC proteins, including specific regulators of comple- 
ment, decay accelerating factor and CD59 [52]. The func- 
tional assay performed in the cited work revealed that 
avidin cross-links RBC membrane regulators of comple- 
ment, thus inactivating cellular defence against comple- 
ment [52]. 
Our preliminary data suggest that interaction of B-RBC 
with immobilized streptavidin induces redistribution of 
biotinylated regulators of complement, DAF and CD59 in 
the RBC membrane. These regulators diffuse to the basal 
surface of the bound B-RBC, became tethered to avidin 
and thus effectively denude the apical surface of the 
B-RBC (A. Zaltsman, unpublished results). Therefore, the 
apical surface, depleted of membrane regulators of com- 
plement, may be spontaneously attacked by complement. 
As Fig. 3 shows, induction of hemolytic susceptibility 
required a much higher surface density of immobilized 
avidin than was needed for stable binding of B-RBC, 
presumably reflecting an increased capacity of immobi- 
lized avidin at higher densities to bind membrane proteins 
diffusing in from the apical surface of the bound B-RBC. 
Presumably, other biotinylated proteins in the B-RBC 
membrane also contribute to B-RBC anchoring to immobi- 
lized avidin. Moreover, these proteins also may diffuse 
from the apical surface of the target-bound B-RBC to their 
basal surface, and thus contribute to destabilization of the 
B-RBC membrane. 
In conclusion, our present results clearly demonstrate 
that B-RBC bind to avidin targeted to biotinylated anti- 
body bound to immobilized antigen. Bound cells activate 
complement and are readily lysed. This data should aid in 
the design of immunoerythrocytes for targeted elivery 
and local release of a drug. Further in vivo studies are 
needed to address the important issues of safety and 
effectiveness of this targeting strategy. Our preliminary 
data obtained in rats suggest that not only lysis by comple- 
ment, but opsonization without lysis may contribute in 
liver- and spleen-mediated limination of streptavidin- 
carrying B-RBC from circulation. Such uptake may lead to 
toxicity of drug loaded RBC towards liver and spleen. The 
results of our animal experiments, however, suggest hat 
the major portion of streptavidin-free B-RBC injected 
intravenously circulates in the bloodstream for a prolonged 
time [34]. Therefore, a two-step strategy (injection of 
biotinylated antibody conjugated with streptavidin or con- 
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sequent injection of these proteins followed by injection of 
B-RBC) may be more safe than one-step injection of 
B-RBC carrying streptavidin and biotinylated antibody. 
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